Thermo Fisher Scientific Inc. $TMO Holdings Boosted by Veritas Asset Management LLP

Key Points

• Veritas Asset Management increased its Thermo Fisher stake by 4.4% in the second quarter, holding 882,873 shares valued at approximately $442.6 million. Institutional investors collectively own 89.23% of the company.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $619.41. Recent targets range from $520 to $650, while Thermo Fisher reported quarterly EPS and revenue above expectations.
• TMO traded at $603.43, near its $647 one-year high, and announced a quarterly dividend of $0.47 per share. Company insiders have sold 73,768 shares worth about $44.1 million over the past 90 days.

Veritas Asset Management LLP lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.4% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 882,873 shares of the medical research company's stock after purchasing an additional 36,878 shares during the period. Thermo Fisher Scientific comprises 8.2% of Veritas Asset Management LLP's investment portfolio, making the stock its 6th biggest position. Veritas Asset Management LLP owned about 0.24% of Thermo Fisher Scientific worth $442,637,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Bank OZK purchased a new stake in shares of Thermo Fisher Scientific in the second quarter valued at approximately $1,096,000. Ausdal Financial Partners Inc. acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at about $456,000. North Dakota State Investment Board purchased a new position in Thermo Fisher Scientific in the fourth quarter worth approximately $7,505,000. BlackRock Inc. acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at $15,501,867,000. Finally, German American Bancorp Inc. purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth $4,920,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Jefferies Financial Group reissued a "buy" rating and set a $630.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Morgan Stanley increased their price objective on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an "overweight" rating in a research report on Friday, July 24th. CLSA started coverage on shares of Thermo Fisher Scientific in a research note on Thursday, September 3rd. They set an "outperform" rating and a C$748.00 target price for the company. Royal Bank Of Canada raised their price target on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a "sector perform" rating in a research note on Friday, July 24th. Finally, Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They set a "market perform" rating and a $520.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and an average target price of $619.41.

Thermo Fisher Scientific Stock Performance

TMO traded down $10.35 on Tuesday, reaching $603.43. The company had a trading volume of 2,695,109 shares, compared to its average volume of 2,241,478. The stock has a 50-day moving average price of $575.12 and a 200-day moving average price of $516.59. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $647.00. The stock has a market capitalization of $223.12 billion, a PE ratio of 32.46, a P/E/G ratio of 2.57 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to analysts' expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business's revenue was up 10.5% on a year-over-year basis. During the same period in the prior year, the firm earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.11%.

Insider Activity at Thermo Fisher Scientific

In other news, VP Lisa Britt sold 11,440 shares of the business's stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the transaction, the vice president directly owned 14,784 shares in the company, valued at $9,064,366.08. The trade was a 43.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Michael Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares in the company, valued at $12,596,400. This represents a 54.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 73,768 shares of company stock worth $44,122,820 in the last 90 days. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.